Delivering the goods: Realizing the clinical potential of RNAi

Nanomedicine

Volumn 4, Issue 6, 2009, Pages 595-598

  Howard, Kenneth Alan ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ARGINYLGLYCYLASPARTIC ACID; CYCLODEXTRIN; MACROGOL; MICRORNA; NANOPARTICLE; POLYETHYLENEIMINE; SMALL INTERFERING RNA; TRANSFERRIN; VASCULOTROPIN;

ARTHRITIS; CLINICAL TRIAL; EDITORIAL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE INTERACTION; GENE SILENCING; GENE TARGETING; GENE TRANSFER; HUMAN; INNATE IMMUNITY; KIDNEY CLEARANCE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; RNA CLEAVAGE; RNA DEGRADATION; RNA INTERFERENCE; SOLID TUMOR;

HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 70349143187     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.45     Document Type: Editorial

References (23)

1. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J: Interfering with disease: a progress-report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6, 443-453 (2007).
2. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ: Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23, 222-226 (2005).
3. Morris KV, Chan SW, Jacobsen SE, Looney DJ: Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305, 1289-1292 (2004).
4. He L, Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522-531 (2004).
5. Howard KA: Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv. Drug Deliv. Rev. 61, 710-720 (2009).
6. Schiffelers RM, Ansari A, Xu J et al.: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149 (2004).
7. Bartlett DW, Davis ME: Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 99, 975-985 (2008).
8. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG: Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release 129, 107-116 (2008).
9. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M: Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319, 627-630 (2008).
10. Takeshita F, Minakuchi Y, Nagahara S et al.: Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl Acad. Sci. USA 102, 12177-12182 (2005).
11. Ishimoto T, Takei Y, Yuzawa Y et al.: Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity. Mol. Ther. 16, 387-395 (2008).
12. Baigude H, Mccarroll J, Yang CS, Swain PM, Rana TM: Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem. Biol. 2, 237-241 (2007).
13. Zimmermann TS, Lee AC, Akinc A et al.: RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114 (2006).
14. Thomas M, Lu JJ, Ge Q, Zhang C, Chen J, Klibanov AM: Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc. Natl Acad. Sci. USA 102, 5679-5684 (2005).
15. Howard KA, Rahbek UL, Liu X et al.: RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14, 476-484 (2006).
16. Rahbek UL, Howard KA, Oupicky D et al.: Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides. J. Gene Med. 10, 81-93 (2008).
17. Robbins M, Judge A, Ambegia E et al.: Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 19, 991-999 (2008).
18. Robbins M, Judge A, Maclachlan I: siRNA and innate immunity. Oligonucleotides 19, 89-102 (2009).
19. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J: Chitosan/siRNA nanoparticle-mediated TNF-α knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol. Ther. 17, 162-168 (2009).
20. Judge AD, Bola G, Lee AC, Maclachlan I: Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494-505 (2006).
21. Akhtar S, Benter I: Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. 59, 164-182 (2007).
22. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984-8992 (2005).
23. Heidel JD, Yu Z, Liu JY et al.: Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl Acad. Sci. USA 104, 5715-5721 (2007).